# Advanced Oncotherapy Plc Another year of significant development

- Link: https://www.directorstalkinterviews.com/advanced-oncotherapy-plc-another-year-significant-development/412730784
- Published: 2017-06-26T07:21:24+01:00
- Author: Giles Arbor

**Advanced Oncotherapy Plc** (LON:AVO), the developer of next generation proton 
therapy systems for cancer treatment, announced today it’s audited results for the
year ended 31 December 2016, another year of significant development of the Company’s
LIGHT system.

**Highlights:**

· First successful acceleration of the proton beam through the proton source and
Radio Frequency Quadrupole (RFQ)

· Successful high power testing of the Side Coupled Drift Tube Linac

· Harley Street planning permission granted in October 2016

· Thales manufacturing agreement signed with the objective of seeing eight LIGHT
systems produced each year

· Further funds raised through Placing & Open Offer

· Ongoing discussions regarding additional commercial opportunities for LIGHT installations

· Shareholder funds of £34 million at 31 December 2016

**Post Period End Events & Technical Milestones**

· Technical milestones reached and further progress made

· Management team strengthened further with key hires

· Deconstruct (UK) Ltd appointed as principal contractor at Harley Street; shell
and core work well underway

· Financing agreements secured with Bracknor Investment Group and Blackfinch Investment
Ltd with additional financing options under consideration

Nicolas Serandour, CEO of Advanced Oncotherapy, said: “We made significant progress
in 2016 in the commercialisation of our next-generation technology in the treatment
of cancer – LIGHT, and while the year was not without its challenges, we have overcome
these obstacles and look forward to successfully executing on the timelines that
we outlined in March 2017. We should see further considerable progress in the Company
and are confident that we are in a position to deliver against our timetable for
success.”

Posting of Annual Report & Notice of AGM

The annual report for the year ended 31 December 2016 will be available from the
Company’s website at www.advancedoncotherapy.com and will shortly be posted to shareholders
together with a notice of Annual General Meeting to be held at 2pm on Wednesday,
19 July 2017 at the Royal Institute of British Architects, 66 Portland Place, London
W1B 1AD
 **EXECUTIVE CHAIRMAN’S STATEMENT**

**INTRODUCTION**

I am very pleased to report another year of significant progress in our aim of delivering
the ground-breaking LIGHT system (Linac Image Guided Hadron Technology), a next 
generation proton therapy system for treating cancer.

Since 2014, when we first set out detailed timelines for investors, the business
has moved forward and we have adapted to the changing requirements we have faced
as we continued along our journey. Back in 2014 we had no confirmed flagship site,
no customers and no agreements covering our move into production manufacturing. 
Since then we identified a prime site in Harley Street, have partnered with Circle
Health to operate the site, extended our original foot print on site, successfully
gained planning permission for the site and completed the tender process for our
construction partners. Whilst doing all of this we continued to make considerable
advances in the technical development of our first LIGHT system and put in place
the framework agreement with Thales that will ultimately provide Advanced Oncotherapy
with the capacity to mass produce eight LIGHT units annually, to fulfil a pipeline
of interest already established in the UK & Europe, the US and across Asia.

To reflect the changing requirements and opportunities that we faced, in March 2017
we outlined revised timelines for site readiness, patient treatment and technological
development. We are confident that we will deliver to this timeline and remain committed
to hitting these targets and regularly communicating our progress to shareholders.

Our technology and key differentiators

At Advanced Oncotherapy, we will offer healthcare providers affordable systems that
will enable them to treat cancer with an innovative proton therapy technology which
offers better health outcomes for patients and lower treatment related side effects.
Our LIGHT technology offers the following advantages:

· Lower cost: Estimated cost of a multiple treatment room LIGHT facility will be
in the region of USD40 million vs. USD160-200 million for those using cyclotrons
or synchrotrons;

· Precision: The beam energy from a LIGHT machine can be moved very rapidly during
therapy, allowing the beam to more accurately target cancer cells and spare healthy
tissues;

· Compact: LIGHT will be smaller and materially lighter than conventional proton
therapy solutions, significantly reducing the size and construction cost of the 
facility required to house it;

· Modular: LIGHT will be modular in nature providing healthcare operators greater
freedom to customise their service to particular treatments i.e., providing lower
energy accelerators for eye, head or neck treatments, and having the flexibility
to increase this to higher energies through the addition of other modules for other
more deep-seated tumours;

· Lower shielding requirements: LIGHT will require less shielding than conventional
proton therapy solutions.

**TECHNOLOGICAL DEVELOPMENT**

During the year we made significant progress in our technological development of
our first LIGHT system. The proton source, constructed by Pantechnik in France, 
was fully assembled and shipped to Geneva for testing and tuning. The Radio Frequency
Quadrupole (RFQ), the technology licensed from CERN which first accelerates the 
protons to 5MeV, was also assembled at the facility and successfully tested there.

At the end of the year we had fully integrated the proton source and the RFQ, following
a successful testing and calibration programme. Whilst the acceleration and measurements
predicted matched those expected from computer simulations, it was not until after
the year end that the team’s hard work culminated in our biggest technical achievement
to date: the first successful acceleration of the proton beam from 40keV to 5MeV.
The significance of this first acceleration cannot be overemphasized as this is,
by far, the hardest part of the acceleration process to achieve and the stage carrying
the most technical risk. It is also worth remembering that the rest of the technology
for accelerating the proton beam has been validated through the LiBo (Linac Booster)
prototype.

During the year we also performed successful high power testing of the Side Coupled
Drift Tube Linac (SCDTL) module, the accelerating structure positioned after the
RFQ, which will ultimately be used to accelerate the protons to an energy of 20-
25MeV.

Full details of our future key technical milestones are detailed below and we will
continue to update shareholders on our progress as we aim to create a beam capable
of treating superficial tumours by the end of Q3 2018.

**HARLEY STREET**

The availability of the Harley Street site presented us with an enormous opportunity
to showcase our unique technology and demonstrate its suitability for central city
locations and, in particular, the technology’s ability to overcome the challenges
associated with installation in a Grade 2 listed building in a prestigious and well
known centre for medical excellence. Successful planning permission was a key milestone
for the project’s development and, following the appointment of Circle Health as
joint operator in October 2015, the Company was offered the opportunity to increase
the site’s footprint. Whilst this did have an impact on the timing of receipt of
planning permission and building works, ultimately it meant we had the go-ahead 
from Westminster City Council (granted in October 2016) for an enlarged footprint
and capacity to create greater shareholder value in the long term.

Post period end, The Howard de Walden Estate, the landlord of the Harley Street 
site, announced the appointment of Deconstruct (UK) Limited as the principal contractor.
Preparatory works have been carried out and, following receipt of confirmation from
Westminster City Council, Deconstruct have started shell and core work, which is
now well underway.

As we outlined to investors in March 2017 based on initial quotes, on-site excavation
and build times for the core and shell are estimated to take between 62 and 96 weeks
with an additional 52 weeks for full fit-out, including the installation of cooling
systems and power supplies. Whilst these estimates reflect the constraints associated
with working with two listed buildings in a residential area, they compare very 
favourably to building times associated with the construction of multi-room proton
beam facilities using legacy technologies traditionally built in large and remote
areas. The team will endeavour to ensure that all construction and excavation will
be carried out with minimal disruption and disturbance to the residents of Harley
Street and the surrounding areas. We believe that the site will be ready for installation
by H1 2019 and following regulatory approval and commissioning, the first patient
treatment is expected in 2020.

**PRODUCTION & MANUFACTURING**

In February 2016, we signed an industrialisation agreement with Thales to manufacture
and build our completed LIGHT systems. Thales is a global technology leader for 
the Aerospace, Transport, Defence and Security markets.

The first major step of this partnership consisted of initial optimisation studies
undertaken by Thales with the view to commissioning and building two custom-designed
series production lines. This phase is well advanced and the future manufacturing
hub has now been identified in one of Thales’ existing sites at Thonon, France. 
The terms for the manufacturing of the first LIGHT machine were finalised in October
2016. In addition, Thales has already started to carry out high power Radio-Frequency(
RF) testing and conditioning of accelerating modules and sub-systems in its Velizy
site near Paris.

For the second phase of this collaboration, the Company, with the support of Thales,
is committed to building two production lines capable of producing eight machines
per year. We continue working towards strengthening our collaboration through a 
focus on risk and rewards sharing. This approach encompasses both operational and
financial considerations, a pre-requisite for disrupting the market for proton therapy.

**FINANCING**

During the year we raised £10 million (before expenses) through the issue of 10,000,000
new ordinary shares of 25 pence each in the capital of the Company at a price of
100p per New Share to new and existing shareholders. A group of Directors and Senior
Management participated in this funding round and subscribed for a combined total
of 3,155,000 of these shares. In addition, a further 3,378,771 shares were issued
as part of an Open Offer.

At 31 December 2015 the Company had shareholder funds of £27.3 million and at 31
December 2016 the Company had £34 million. The increase of £6.7 million can be explained
through the Company raising new equity funding of £14.2 million and an increase 
in share option reserve of £1.2 million, an increase in the exchange rate movement
reserve of £1.6 million, offset by a retained loss of £10.3 million.

During the year we also agreed access to further funds through an arrangement with
Metric Capital Partners LLP, a Pan-European private capital fund manager, to provide
£24 million of vendor financing for the purchase of the LIGHT machine in Harley 
Street. Whilst we subsequently removed the condition requiring a further £25 million
cash or capital injection we have not yet drawn down on the facility, although the
option to do so remains available to us.

Following the year end, we secured a flexible and staged £26 million financing agreement
with Bracknor Investment Group, a Dubai based investment firm. The agreement gives
the Company the ability to issue a minimum of £13 million in convertible loan notes(
Minimum Requirement), in tranches of £1.3 million each, up to a maximum, at the 
Company’s sole discretion, of £26 million over 24 months, and was approved by shareholders
at our General Meeting. The Company has a further option to raise up to an additional
£26 million, on the same terms, for a potential total commitment of £52 million,
provided issuance of the initial £26 million has occurred within the first two years.

In addition to this we signed a 12 month convertible and redeemable loan in March
and June 2017 with Blackfinch Investment Ltd, at a conversion price of 100p, which
provides net funding of £6.5 million. This agreement provides the Company with additional
financing to complement the Bracknor financing facility and offers us added flexibility
in terms of forthcoming financing requirements.

We continue to consider additional financing options, including non-dilutive financing,
the facility with Metric Capital, and other possibilities and with these two funding
options in place we have strengthened the position from which we approach these 
options.

**PIPELINE**

As well as our facility in Harley Street, we have a number of commercial opportunities
in the pipeline. In the USA, we are currently in ongoing discussions with three 
different sites in which we would install the LIGHT system. Site one is a one room
system with the potential for a second room. The second and third sites are both
two room systems. We also have a potential project in Spain and one in Italy. In
terms of China and the rest of Asia, we are in ongoing discussions with key stakeholders
to determine what the best way to proceed is. There are also opportunities in the
Middle East and Australia with discussions underway at leading academic and clinical
centres and we will update the market with further progress in our sales pipeline.

**PEOPLE**

In 2016, we decided to realign the roles and responsibilities of the Executive team
to add additional focus on operational functions. We decided that my roles of Executive
Chairman of Advanced Oncotherapy and Chief Executive Officer be split. With that
in mind, Nicolas Serandour was promoted to Chief Executive Officer, after joining
the Company as Chief Financial Officer in September 2014 and then taking on the 
additional role of Chief Operating Officer in February 2016. This change was important
as the agreement with Thales marked a shift in the business from just focussing 
on the development of the first LIGHT system, to the ongoing commercial roll-out
of the game-changing technology. The future commercial development of the business
will be critical to the long-term success and value creation within the Company.

We also appointed Michel Baelen to the Company as Head of Regulatory Affairs, Gerardo
d’Auria as a new Technical Director and Ed Lee as Senior Vice President of Operations;
in June 2017, Ed was appointed Chief Operating Officer.

**SINOPHI**

In February 2017, we reached an agreement with Sinophi to terminate the purchase
orders announced on 25 March 2015 and 21 October 2015. We have retained our full
distribution rights for the LIGHT system in China and South East Asia and are now
in a position to speak to hospitals, clinics, potential distribution partners and
advisory bodies in the region. Although these events were disappointing for us, 
it did not take away from the fact that we still expect to see high demand for our
first product, particularly in Asia, and continue to focus on the completion of 
our first installation.

**OUTLOOK FOR 2017**

As per our update in March 2017, the Harley Street facility will be the first site
in the UK where the LIGHT system will be installed. Alongside our partners CircleHealth,
we are also in discussions to build a system at a new hospital in Birmingham. We
are in advanced negotiations with a number of sites in the USA, Europe, Asia and
the Middle East. Based on this, we are confident that we will secure additional 
commercial sales in the near future.

In addition, a number of meetings have been held with regulatory bodies in Europe,
the US and China, which provides us with the confidence we need to pursue a valid
path to ensure future regulatory approvals.

A summary of the key technical milestones is provided below:

  |  By end Q2 2017 |  Delivery of all CCL units |  
 |  Beam fired through RFQ |  
 |  By end Q4 2017 |  Beam through SCDTLs at an energy of 20-25MeV |  
 |  Development of the Patient Positioning System |  
 |  By end Q2 2018 |  Beam fired through the first CCL |  
 |  Directional dose delivery system (or Nozzle) ready for installation |  
 |  By end Q3 2018 |  Beam capable of treating superficial tumours |

Although much of 2016 was a challenging time, we have overcome the obstacles that
we have come up against and look forward to successfully executing on the timelines
that we outlined in March 2017. We should see further considerable progress in the
Company and are confident that we are in a position to deliver against our timetable
for success.

We believe in people and the team around us involves some of the leading experts
in their chosen fields. We are ideally placed with the right product and at the 
right time to enter a market with explosive growth rates. Our technology is disruptive
and has the power to change the face of cancer treatment around the world. We have
a clear path or commercial success with significant milestones coming this year.
On behalf of all of our shareholders, I would like to thank them for their continued
support and belief, and I look forward to further success ahead.

Dr. Michael Sinclair

Advanced Oncotherapy Plc Executive Chairman

23 June 2017

Share on:
